Daclizumab

Daclizumab is a monoclonal antibodies that prevent T-lymphocytes proliferation. Daclizumab is used for prophylaxis of acute rejection in allogenic renal transplantation. Daclizumab is usually given in combination with ciclosporin and corticosteroid immunosuppression regimens.

Brands
ZENAPAX
Adult Dose
Dose: 1 mg/kg
Single Dose: 1 (1)
Frequency: As recommended.
Route: IV
Instructions: Within 24 hrs before transplantation. Then every 14 days for a totalof 5 doses.
Neonatal
Paedriatic
Characteristics
. It is of Natural origin. . The Molecular Weight of Daclizumab is 142612.10.
Contraindications
Daclizumab is contraindicated in conditions like Pregnancy,Breast feeding.
Effects
The severe or irreversible adverse effects of Daclizumab, which give rise to further complications include Peripheral edema, Cardiac arrest, Anaphylactic reactions, Lymphoproliferative disorders, Respiratory failure, Laryngeal oedema.The symptomatic adverse reactions produced by Daclizumab are more or less tolerable and if they become severe, they can be treated symptomatically, these include Headache, Fatigue, Rashes, Urticaria, Tremor, Hypersensitivity reactions, Bronchospasm, Hypertension, Wheezing, GI disturbance, Burnning sensation of hands, and feets.
Indications
Daclizumab is primarily indicated in conditions like Metastatic.
Interactions
No data regarding the interactions of Daclizumab was found.
Interfrence
Risks
Drug should not be given to Pregnant Mothers, and Cardiac / Hypertensive Patients.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
Warnings
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.